(Ben Sellers, Headline USA) When President Donald Trump’s first round of multi-trillion-dollar coronavirus tax rebates arrived, I was fortunate enough to be in a position where it was pure gravy.
My expenses (including the skyrocketing costs of a public healthcare option) were rising, but the biggest area of need for me was fluid investments in case of impending disaster—and with the markets having just bottomed out, the time seemed ripe to reap the rewards.
Learning the Ropes
I briefly flirted with vaccine companies like Moderna and Pfizer but couldn’t deal with the uncertainty. Ditto for lockdown-friendly investments like Zoom, which proved a regular roller-coaster ride as they fine-tuned their products to meet mass demand.
I signed up for a Bitcoin exchange, but I remain oblivious to the logistics of a cyber-currency and wary of who controls all the levers (as if the Federal Reserve weren’t shady enough).
I largely avoided the so-called FAANG companies—the traditional tech blue chips of Facebook, Amazon, Apple, Netflix and Google—not only due to my disdain for their increasingly aggressive political influence, but also their stock price tags.
Of course, it would be remiss of me not to mention my investment in precious metals—in particular, my favorite keepsake: Trump silver rounds and “Don’t Tread on Me” silver rounds featuring the iconic snake from the Gadsden flag. But I bought those more for financial protection—to hold their value—than as an investment.
A Shift in Strategy
After the inevitable outcome of the bitterly disputed 2020 election came more into focus, I became increasingly cynical about the prospects that lay ahead.
I had grown frustrated with seeing some of my early investments, like Moderna, take off only after I had unloaded them. But I had seen just enough success in biomedical investments, including Abbott Laboratories, which makes antibody tests, and Lonza, one of the companies partnering with Moderna to produce the vaccine.
I also was lucky enough to get in early on two companies that are at the forefront of gene therapies: Editas and CRISPR. Initially they caught my eye due to their cutting-edge COVID research, and when CRISPR’s founders won the Nobel Prize in medicine, I knew I was onto something. But for now, their meteoric rise seems to be tapering off, making them a less reliable investment strategy.
After giving up early on 3M, I also invested in McKesson Corp., one of the emerging leaders in personal-protective equipment such as masks, and Aramark, which seems poised to play a big role in the effort to support schools with their COVID-sterilization efforts.
I had learned two things, which seem obvious in retrospect: Buy in on companies before the buzz, and don’t sell off at the first sign of trouble if you’re confident in your research and your information.
With that in mind, I tried to shift my focus to the sea-change of policies that would be implemented under a Democrat administration but were not yet on the radar.
Below is an overview of the areas where I am now shifting my focus, and the often corrupt reasons for thinking they might have a bright financial future amid the dark winter of America’s declining years as a dominant, freedom-loving super-power.
- Chinese telecoms and pharmaceuticals
Through executive order, President Donald Trump has frozen several stocks alleged to support China’s state-run military, including one I had been investing in.
But in light of the Hunter Biden scandals and the cozy relationship that Biden advisers like presumptive Secretary of State Tony Blinken have with Chinese donors, it is only a matter of time before the kimono opens back up.
China’s advances in 5G technology have been hindered considerably by Trump’s prohibitions, blocking US companies in large part from doing business with the major brands like Huawei (long believed to be used for spying on its own citizens and others).
But wait for them to come roaring back with a vengeance when the cap is lifted and to be at the forefront of the emerging broadband network.
And while I, personally, would sooner imbibe a cocktail of broken glass and rusty nails than inject Sinovac—China’s cheaper, 50%-effective coronavirus vaccine—in my own bloodstream, the communist nation is brokering deals throughout the globe to have it be the go-to treatment for Third-World countries.
- Green New Deal / Medicare-for-all beneficiaries
Domestically, the Biden administration’s implementation of socialist-friendly wealth-redistribution programs is sure to be a cash bonanza for green energy in particular.
Smart investors would already have gotten in on Elon Musk’s Tesla several months ago, but I missed the electric-powered bandwagon.
Nonetheless, Musk, ever the fearless innovator, is sure to take his status as the world’s new richest man into interesting, uncharted territory.
As for me, one of the companies hoping to compete with Tesla, Nikola, seemed more enticing.
Fresh off a failed deal with General Motors, the green-energy upstart was nearly bottoming out when I decided to grab it, and it continued to fall. But my faith was unshaken, and I have already recouped my losses from buying on the temporary downturn.
While I have not yet begun to dig into medical start-ups, my guiding beacon in doing so will be StartUp Health, the healthcare incubator co-founded by Howard Krein, who happens to be Joe Biden’s son-in-law.
- Dystopian pioneers
If and when the “great reset” comes, those at the forefront of privacy-invasion will lead the way. In particular, I am keeping a close eye on defense-related startups tied to Blinken’s WestExec Advisors.
One of the most intriguing is Shield AI, a small San Diego firm specializing in developing artificial intelligence systems in drones, which already has major defense contracts in the pipeline.
But many of the startups, including Shield AI, remain private at the moment. So I did the next best thing by investing in BCLS (Bain Capital Life Sciences) Acquisition, which has been linked to strategic partnerships with some of WestExec’s investment gems.
Those cutting-edge companies won’t be the only ones cashing in, however.
Fossils of the old telecom conglomerates may also come roaring back. In particular, IBM caught my eye.
The company that developed the very first computer is one of several scrambling to adapt a digital passport app that will allow those who received COVID vaccinations to confirm their status and medical details for things like attending public events and traveling abroad.
Something about this absolutely terrifying technology trend feels the same as getting in on the ground level of the original vaccine-development gold-rush back in March and April.
- Vote-fraud conspirators/political cronies
AT&T, despite owning major entertainment subsidiaries such as TimeWarner, has surprisingly faltered in recent years, whether laying low to avoid anti-trust action or simply struggling to keep up with changing communications paradigms like “free” text and video-conferencing apps (paid for in privacy sacrifices).
The telecom dinosaur was even looking to unload one of its prize subsidiaries, CNN, due to its struggling ratings—although the fake-news network and prime Trump antagonizer may benefit from Biden’s arrival and the decline of Fox News.
But what sold me on AT&T was an eerie connection to the vote-fraud scandal during the 2020 election.
The telecom company hired Bill Kennard, the former FCC chair and EU ambassador during the Clinton and Obama presidencies, to be its new board chair starting this month.
Does Kennard have Biden’s ear like he did the two Democrat precursors’? Well, he also happens to be part of the three-person chair of Staple Street Capital—the company that owns Dominion Voting Systems.
In fact, his resume suggests that Kennard is something of a deep-state Forrest Gump, with his hand in every shady operation orchestrated by the Left’s power-grabbers.
Conveniently, after I began buying AT&T, it became the center of a short-lived news cycle when its Nashville regional headquarters was targeted by a Christmas Day bombing attack.
Despite the official story-line from the FBI and others, that it was a rogue, disgruntled eccentric who died in the process, conspiracy theories hinted at the possibility that AT&T might have been—for reasons unknown—storing some of the Dominion voting machines pending an audit.
- Iranian and Russian Energy Cultivation
One thing that never quite added up to me about the Russia-collusion hoax and the Ukrainian Burisma scandals was why.
What was it about that disputed region around the Crimean peninsula that was so strategically important, it not only warranted a US-backed coup of Ukraine, but also was worth staking Americans’ faith in US democracy on?
To the best I can surmise, it all relates to the extraordinarily lucrative energy market—not only as it relates to the US supply chain, but also Western Europe, which has no prospects for exploring and cultivating oil fields of its own.
Trump’s advisers, including George Papadopoulos, supported shifting a proposed pipeline from Iran’s sphere of influence through Turkey and instead routing it through Israel and Greece.
The dynamics involved in this mother-of-all-geopolitical-shadow-wars is well beyond my pay-grade, but suffice it to say, it roiled many of the left-leaning Western intelligence apparati. That may have been linked, in part, to the threat it posed to the failed Iran nuclear deal.
Meanwhile, a declassified memo that surfaced in connection with the Senate’s investigations of Hunter Biden signaled that his rationale for joining the board of Burisma in 2014 was to capitalize on the destablization of the European energy markets following the country’s ouster of its pro-Russia president.
Regardless of whether the Bidens’ personal finances are still tied in the region (my bet is that they are), the ideological realignment will now be friendlier to companies—even corrupt ones—that undermine Russia’s cornering of the market.
While few are publicly traded in US markets, one of those involved in the exploration and pipeline developments alongside Burisma is BP. It could get the early edge over more US reliant oil-producers who will be hit by new domestic energy regulations.
As an added bonus, BP quickly learned the benefit of virtue-signaling during the Obama era, when the former president hit them hard over the Deepwater Horizon explosion and resulting oil spill off the coast of Louisiana.
The company hasn’t relented since, turning from what Rolling Stone called “the world’s most dangerous oil company” to one of its favored corporate partners.
Betting on Evil?
In applying these new investment principles, I felt a bit like circa-2008 George Soros.
The reviled vulture-capital icon and New-World-Order financier doubled-down heavily on the Chinese yuan as the US housing bubble crashed and a rapid devaluation of the dollar came from the injection of billions in troubled-asset relief funds for Obama’s “shovel-ready” pet projects.
But in a way, there is something cathartic and therapeutic about cynically investing in industries and fields that represent the antithesis of all that I believe in.
In some cases, my infiltration of the left’s financial capital networks has proved a healthier and more constructive way to indulge my conspiratorial instincts than, say, storming the US Capitol on behalf of Q and the Kraken.
As Soros, himself, has rationalized—when reflecting on his halcyon days of helping Nazis confiscate property from his fellow Hungarian Jews during the Holocaust—the inevitable travesty of the coming years is going to happen regardless, so why not cash in?
“There was no sense that I shouldn’t be there,” Soros said in a 1998 interview with 60 Minutes.
“In a funny way, it’s just like in markets, that if I weren’t there—of course, I wasn’t doing it—but somebody else would,” he continued. “. . . I was only a spectator. The property was being taken away. So, I had no role in taking away that property. So, I had no sense of guilt.’
Any spoils I reap from investing in the Biden administration’s corruption won’t be quite so immoral as Soros’s (I hope), but whatever money I reap from them stays out of the hands of the oligarchal globalist hegemony.